Magazine Article | February 1, 2021

Companies To Watch: Akero Therapeutics

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Akero Therapeutics is developing drugs for metabolic diseases and has a weekly dosed compound, efruxifermin (EFX), heading for a Phase 2b/3 adaptive clinical trial for treating the common liver disease, NASH (non-alcoholic steatohepatitis). Originally licensed from Amgen, EFX mimics fibroblast growth factor 21 (FGF21) to reduce liver fat, inflammation, and fibrosis. Because FGF21 regulates many metabolic pathways and cellular processes, the company aims to explore the potential for EFX in other therapeutic areas.

access the Magazine Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader

Please tell us more about you so that we can customize our newsletters to your specific interests: